論文

査読有り 筆頭著者 国際誌
2019年12月27日

Biological Effects of Anti-RANKL Antibody and Zoledronic Acid on Growth and Tooth Eruption in Growing Mice.

Scientific reports
  • Motoki Isawa
  • Akiko Karakawa
  • Nobuhiro Sakai
  • Saki Nishina
  • Miku Kuritani
  • Masahiro Chatani
  • Takako Negishi-Koga
  • Masashi Sato
  • Mitsuko Inoue
  • Yukie Shimada
  • Masamichi Takami
  • 全て表示

9
1
開始ページ
19895
終了ページ
19895
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1038/s41598-019-56151-1

The anti-bone resorptive drugs denosumab, an anti-human-RANKL antibody, and zoledronic acid (ZOL), a nitrogen-containing bisphosphonate, have recently been applied for treatment of pediatric patients with bone diseases, though details regarding their effects in growing children have yet to be fully elucidated. In the present study, we administered these anti-resorptive drugs to mice from the age of 1 week and continued once-weekly injections for a total of 7 times. Mice that received the anti-RANKL antibody displayed normal growth and tooth eruption, though osteopetrotic bone volume gain in long and alveolar bones was noted, while there were nearly no osteoclasts and a normal of number osteoblasts observed. In contrast, ZOL significantly delayed body growth, tooth root formation, and tooth eruption, with increased osteoclast and decreased osteoblast numbers. These findings suggest regulation of tooth eruption via osteoblast differentiation by some types of anti-resorptive drugs.

リンク情報
DOI
https://doi.org/10.1038/s41598-019-56151-1
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/31882595
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934544
ID情報
  • DOI : 10.1038/s41598-019-56151-1
  • PubMed ID : 31882595
  • PubMed Central 記事ID : PMC6934544

エクスポート
BibTeX RIS